ArticleJournal of enzyme inhibition and medicinal chemistry2022
Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and
Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 70 citations in OpenAlex.
- Phthalazine scaffolds in medicinal chemistry: a review of their synthesis, versatility, and pharmacological significance.Molecular diversity · 2026Review
- Phthalazine-based quaternary ammonium salts: synthesis, biological evaluation and membrane-targeting mechanism againstFrontiers in microbiology · 2026Article
- Influence of Pyridine Entangled Novel Hybrid Quinoxaline Spirane on the Fluorescence and Absorption Spectra of Biomolecules: Molecular Docking, Pharmacokinetic, and In-Vitro Biological Investigations.Journal of fluorescence · 2025Article
- Targeted synthesis of a trimethoxyphenyltetrahydropyrimidine analogue designed as a DNA intercalator:RSC advances · 2025Article
- Novel dual action chimera doxorubizen demonstrates superior efficacy to doxorubicin in acute leukemia.Scientific reports · 2025Article
- Recent advances on anticancer activity of benzodiazine heterocycles through kinase inhibition.RSC advances · 2025Review
- Design and synthesis of new nicotinamides as immunomodulatory VEGFR-2 inhibitors and apoptosis inducers.Future medicinal chemistry · 2024Article
- New imidazole-2-thiones linked to acenaphythylenone as dual DNA intercalators and topoisomerase II inhibitors: structural optimization, docking, and apoptosis studies.Journal of enzyme inhibition and medicinal chemistry · 2024Article
- 6-Bromo quinazoline derivatives as cytotoxic agents: design, synthesis, molecular docking and MD simulation.BMC chemistry · 2024Article
- Article
- Design, synthesis, molecular modelling and antitumor evaluation ofJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Investigating the potential anticancer activities of antibiotics as topoisomerase II inhibitors and DNA intercalators:Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Carboranyl-1,8-naphthalimide intercalators induce lysosomal membrane permeabilization and ferroptosis in cancer cell lines.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Biological evaluation, docking studies, andJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Design and synthesis of novel rigid dibenzo[Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Design and synthesis of new spirooxindole candidates and their selenium nanoparticles as potential dual Topo I/II inhibitors, DNA intercalators, and apoptotic inducers.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Identification of new theobromine-based derivatives as potent VEGFR-2 inhibitors: design, semi-synthesis, biological evaluation, andRSC advances · 2023Article
- Article
- 1-Benzyl-5-bromo-3-hydrazonoindolin-2-ones as Novel Anticancer Agents: Synthesis, Biological Evaluation and Molecular Modeling Insights.Molecules (Basel, Switzerland) · 2023Article
- Ligand-based design, synthesis, computational insights, andJournal of enzyme inhibition and medicinal chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research presents the design and synthesis of a novel series of phthalazine derivatives as Topo II inhibitors, DNA intercalators, and cytotoxic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.